NASDAQ:ARVN Arvinas Q2 2024 Earnings Report $8.92 -0.17 (-1.87%) Closing price 05/26/2026 04:00 PM EasternExtended Trading$9.09 +0.17 (+1.94%) As of 04:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Arvinas EPS ResultsActual EPS-$0.49Consensus EPS -$1.08Beat/MissBeat by +$0.59One Year Ago EPS-$1.25Arvinas Revenue ResultsActual Revenue$76.50 millionExpected Revenue$33.27 millionBeat/MissBeat by +$43.23 millionYoY Revenue Growth+40.40%Arvinas Announcement DetailsQuarterQ2 2024Date7/30/2024TimeBefore Market OpensConference Call DateTuesday, July 30, 2024Conference Call Time7:00AM ETUpcoming EarningsArvinas' Q2 2026 earnings is estimated for Wednesday, August 5, 2026, based on past reporting schedules, with a conference call scheduled at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Arvinas Earnings HeadlinesInsider Selling: Arvinas (NASDAQ:ARVN) CEO Sells $19,969.36 in StockMay 25 at 5:50 AM | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Arvinas Holding Company (ARVN)May 23, 2026 | theglobeandmail.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today. | Profits Run (Ad)Arvinas Employees Give Back During Company-wide Impact DayMay 18, 2026 | globenewswire.comBullish: Analysts Just Made A Noticeable Upgrade To Their Arvinas, Inc. (NASDAQ:ARVN) ForecastsMay 16, 2026 | finance.yahoo.comEarnings Beat: Arvinas, Inc. (NASDAQ:ARVN) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsMay 15, 2026 | uk.finance.yahoo.comSee More Arvinas Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Arvinas? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Arvinas and other key companies, straight to your email. Email Address About ArvinasArvinas (NASDAQ:ARVN) (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems. The company’s most advanced clinical candidates address hormone-driven cancers. ARV-110 (bavdegalutamide) is being evaluated for the treatment of metastatic castration-resistant prostate cancer, while ARV-471 (voredabolu) is in development for ER+/HER2- breast cancer. Both programs have shown favorable pharmacokinetic profiles in early-phase trials and reflect Arvinas’s strategy of advancing a focused pipeline of next-generation small molecules designed to degrade pathogenic proteins. Since its founding in 2013 and incorporation in New Haven, Connecticut, Arvinas has established collaborative partnerships with leading pharmaceutical companies to expand the reach of its PROTAC platform. Agreements with Pfizer and Roche, among others, provide access to complementary expertise in oncology and other therapeutic areas. The company conducts research and development in the United States and maintains relationships with regulatory authorities in North America and Europe as it pursues global clinical development. Arvinas is led by President and Chief Executive Officer Robert A. Ross, who joined the company in 2022 following a tenure at a major pharmaceutical association. Under his leadership, the company continues to advance its pipeline while building a broader platform for targeted protein degradation. Arvinas remains committed to translating its scientific innovations into transformative therapies for patients with unmet medical needs. View Arvinas ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AutoZone's Pullback Sets Up a Long-Term Buying OpportunityAST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in FocusPowerhouse Williams-Sonoma Heading to Fresh Highs in 2026Why BJ’s Wholesale Club Stock Could Be Ready for a ReboundRocket Companies Turns Around, But Mortgage Risk RemainsAfter NVIDIA, Broadcom's Earnings Are Next—Here's What to WatchRoss Stores Earnings Beat Sends Stock To New Highs Upcoming Earnings Autodesk (5/28/2026)Costco Wholesale (5/28/2026)Canadian Imperial Bank of Commerce (5/28/2026)Dell Technologies (5/28/2026)Royal Bank Of Canada (5/28/2026)Toronto Dominion Bank (5/28/2026)Palo Alto Networks (6/2/2026)Broadcom (6/3/2026)CrowdStrike (6/3/2026)Medtronic (6/3/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
